FDA Letter Blasts Infusion Options Over Sterility Concerns at Facility
The FDA has handed Infusion Options a warning letter for a slew of GMP deficiencies in compounding sterile products and failing to meet 503B conditions for outsourced compounding operations.
Source: Drug GMP Report